Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Sells $557,250.00 in Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Mva Investors, Llc sold 75,000 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $7.43, for a total transaction of $557,250.00. Following the transaction, the insider now directly owns 618,524 shares of the company’s stock, valued at $4,595,633.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Mva Investors, Llc also recently made the following trade(s):

• On Friday, May 3rd, Mva Investors, Llc sold 60,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $7.61, for a total value of $456,600.00.

Tango Therapeutics Trading Up 0.3 %

Shares of TNGX stock opened at $7.61 on Friday. The company’s fifty day moving average price is $8.58 and its 200-day moving average price is $9.31. The stock has a market cap of $812.29 million, a PE ratio of -6.92 and a beta of 0.84. Tango Therapeutics, Inc. has a 12 month low of $2.47 and a 12 month high of $13.03.

Tango Therapeutics (NASDAQ:TNGX) last posted its quarterly earnings data on Monday, March 18th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.04). Tango Therapeutics had a negative return on equity of 41.96% and a negative net margin of 278.55%. The business had revenue of $5.43 million for the quarter, compared to the consensus estimate of $7.86 million. On average, sell-side analysts forecast that Tango Therapeutics, Inc. will post -1.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on TNGX shares. Piper Sandler began coverage on Tango Therapeutics in a report on Monday, February 12th. They set an “overweight” rating and a $18.00 target price for the company. Cantor Fitzgerald began coverage on shares of Tango Therapeutics in a research report on Thursday, April 4th. They issued an “overweight” rating for the company. Wedbush reiterated an “outperform” rating and set a $18.00 price target on shares of Tango Therapeutics in a research report on Monday, March 18th. Finally, HC Wainwright raised their price objective on shares of Tango Therapeutics from $16.00 to $17.00 and gave the stock a “buy” rating in a report on Wednesday, March 20th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $17.25.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AJOVista LLC bought a new position in shares of Tango Therapeutics during the fourth quarter valued at $61,000. Cowen AND Company LLC bought a new stake in Tango Therapeutics during the 4th quarter valued at about $99,000. China Universal Asset Management Co. Ltd. raised its holdings in Tango Therapeutics by 421.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,793 shares of the company’s stock worth $117,000 after buying an additional 9,530 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Tango Therapeutics in the fourth quarter worth approximately $136,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Tango Therapeutics by 570.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,902 shares of the company’s stock valued at $138,000 after buying an additional 11,829 shares during the last quarter. Institutional investors own 78.99% of the company’s stock.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.